Gensight Biologics
Clinical trials sponsored by Gensight Biologics, explained in plain language.
-
Light-Activated gene therapy offers new hope for rare blindness
Disease control OngoingThis study tests a new treatment for retinitis pigmentosa, a genetic eye disease that causes vision loss. Ten adults receive a single injection of gene therapy into the eye, then use special glasses that stimulate the treated cells with light. The goal is to see if the treatment …
Phase: PHASE1, PHASE2 • Sponsor: GenSight Biologics • Aim: Disease control
Last updated May 17, 2026 10:07 UTC
-
Desperate hope: gene therapy shot for one patient with rare blindness
Disease control NO_LONGER_AVAILABLEThis study provided a single patient with Leber Hereditary Optic Neuropathy (LHON) access to an experimental gene therapy called GS010. The treatment was injected into both eyes to try to protect or restore vision. The goal was to check safety, not to cure the disease.
Sponsor: GenSight Biologics • Aim: Disease control
Last updated May 15, 2026 11:55 UTC